Editorial. Talks about the role of hypertriglyceridemia in renal disease progression and its status as the primary lipid abnormality of uremia. Discussion on very low-density lipoproteins; Relevance of findings regarding dyslipidemic mesangial injury to human renal disease; Paradoxes and uncertainties in the role for lipoprotein lipase as an effector and target of treatment in nephrotic and uremic dyslipidemia.